Tested Applications
| Positive IHC detected in | human tonsillitis tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:1000-1:4000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
10927-1-AP targets CXCL13/BCA1 in WB, IHC, IF, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag1358 Product name: Recombinant human CXCL13 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-109 aa of BC012589 Sequence: MKFISTSLLLMLLVSSLSPVQGVLEVYYTSLRCRCVQESSVFIPRRFIDRIQILPRGNGCPRKEIIVWKKNKSIVCVDPQAEWIQRMMEVLRKRSSSTLPVPVFKRKIP Predict reactive species |
| Full Name | chemokine (C-X-C motif) ligand 13 |
| Calculated Molecular Weight | 13 kDa |
| GenBank Accession Number | BC012589 |
| Gene Symbol | CXCL13/BCA1 |
| Gene ID (NCBI) | 10563 |
| RRID | AB_2086050 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | O43927 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
BLR1 (Burkitt lymphoma receptor-1), also called CXCR5, is highly expressed on Burkitt lymphoma cells and B lymphocytes. It may therefore function in the homing of B lymphocytes to follicles. It was reported that the B cell chemokine CXCL13 is elevated in MS serum and cerebrospinal fluid. CXCL13 is also regarded as a proposed serum biomarker of synovitis in RA( Rheumatoid arthritis). CXCL13 consists of a 22-aa signal peptide and a 87-aa mature poly-peptide.
Protocols
| Product Specific Protocols | |
|---|---|
| IHC protocol for CXCL13/BCA1 antibody 10927-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The CXCL13/BCA1 Polyclonal antibody (Cat# 10927-1-AP) has 37 total citations. These appear in journals including Nature Communications, Advanced Materials, Advanced Science, Science Advances, Cell Death & Disease, Cancer Letters, International Journal of Biological Sciences, Clinical Cancer Research, Frontiers in Immunology, FASEB Journal, Journal of Immunology, and others. Research fields span oncology (melanoma, lung, breast, ovarian, gastric, renal, and colorectal cancers), immunology, tertiary lymphoid structures, inflammatory bowel disease, infectious diseases, and neurology.
| Species | Application | Title |
|---|---|---|
Adv Mater Photo-metallo-immunotherapy: Fabricating Chromium-Based Nanocomposites to Enhance CAR-T Cell Infiltration and Cytotoxicity against Solid Tumors | ||
Nat Commun Lymph nodes molecular subtypes unravel lymph nodes heterogeneity and clinical implications in colorectal cancer | ||
Nat Commun B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. | ||
Nat Commun PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial. | ||
Int J Oral Sci Targeting IFN-I driven tertiary lymphoid structures halts B cell-mediated bone loss in periodontitis. | ||
Adv Sci (Weinh) CXCL13 Damages Blood Spinal Cord Barrier by Promoting RNF6/Sqstm1-Ubiquitination Induced Autophagy in Experimental Allergic Encephalomyelitis |



